123 related articles for article (PubMed ID: 19231185)
1. 2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Owen DR; Rodriguez-Lens M; Corless MD; Gaulier SM; Horne VA; Kinloch RA; Maw GN; Pearce DW; Rees H; Ringer TJ; Ryckmans T; Stammen BL
Bioorg Med Chem Lett; 2009 Mar; 19(6):1702-6. PubMed ID: 19231185
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
[TBL] [Abstract][Full Text] [Related]
3. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
[TBL] [Abstract][Full Text] [Related]
4. Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
Coon T; Moree WJ; Li B; Yu J; Zamani-Kord S; Malany S; Santos MA; Hernandez LM; Petroski RE; Sun A; Wen J; Sullivan S; Haelewyn J; Hedrick M; Hoare SJ; Bradbury MJ; Crowe PD; Beaton G
Bioorg Med Chem Lett; 2009 Aug; 19(15):4380-4. PubMed ID: 19553115
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
Sasaki T; Takahashi T; Nagase T; Mizutani T; Ito S; Mitobe Y; Miyamoto Y; Kanesaka M; Yoshimoto R; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4232-6. PubMed ID: 19520574
[TBL] [Abstract][Full Text] [Related]
6. Selective delta opioid receptor agonists for inflammatory and neuropathic pain.
Dondio G; Ronzoni S; Farina C; Graziani D; Parini C; Petrillo P; Giardina GA
Farmaco; 2001; 56(1-2):117-9. PubMed ID: 11347951
[TBL] [Abstract][Full Text] [Related]
7. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
[TBL] [Abstract][Full Text] [Related]
8. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
Guay D; Boulet L; Friesen RW; Girard M; Hamel P; Huang Z; Laliberté F; Laliberté S; Mancini JA; Muise E; Pon D; Styhler A
Bioorg Med Chem Lett; 2008 Oct; 18(20):5554-8. PubMed ID: 18835163
[TBL] [Abstract][Full Text] [Related]
9. Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4268-73. PubMed ID: 19500979
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
Li Y; Liang J; Siu T; Hu E; Rossi MA; Barnett SF; Defeo-Jones D; Jones RE; Robinson RG; Leander K; Huber HE; Mittal S; Cosford N; Prasit P
Bioorg Med Chem Lett; 2009 Feb; 19(3):834-6. PubMed ID: 19097777
[TBL] [Abstract][Full Text] [Related]
11. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution.
Blum CA; Zheng X; Brielmann H; Hodgetts KJ; Bakthavatchalam R; Chandrasekhar J; Krause JE; Cortright D; Matson D; Crandall M; Ngo CK; Fung L; Day M; Kershaw M; De Lombaert S; Chenard BL
Bioorg Med Chem Lett; 2008 Aug; 18(16):4573-7. PubMed ID: 18662872
[TBL] [Abstract][Full Text] [Related]
12. Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
McCauley JP; Dantzman CL; King MM; Ernst GE; Wang X; Brush K; Palmer WE; Frietze W; Andisik DW; Hoesch V; Doring K; Hulsizer J; Bui KH; Liu J; Hudzik TJ; Wesolowski SS
Bioorg Med Chem Lett; 2012 Jan; 22(2):1169-73. PubMed ID: 22197139
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine.
Yoshizumi T; Miyazoe H; Ito H; Tsujita T; Takahashi H; Asai M; Ozaki S; Ohta H; Okamoto O
Bioorg Med Chem Lett; 2008 Jul; 18(13):3778-82. PubMed ID: 18515099
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Becknell NC; Dandu RR; Lyons JA; Aimone LD; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(1):186-9. PubMed ID: 22153342
[TBL] [Abstract][Full Text] [Related]
15. Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
Mizutani T; Nagase T; Ito S; Miyamoto Y; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2008 Dec; 18(23):6041-5. PubMed ID: 18952421
[TBL] [Abstract][Full Text] [Related]
16. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Le Bourdonnec B; Windh RT; Ajello CW; Leister LK; Gu M; Chu GH; Tuthill PA; Barker WM; Koblish M; Wiant DD; Graczyk TM; Belanger S; Cassel JA; Feschenko MS; Brogdon BL; Smith SA; Christ DD; Derelanko MJ; Kutz S; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
J Med Chem; 2008 Oct; 51(19):5893-6. PubMed ID: 18788723
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.
Ogiyama T; Inoue M; Honda S; Yamada H; Watanabe T; Gotoh T; Kiso T; Koakutsu A; Kakimoto S; Shishikura J
Bioorg Med Chem; 2014 Dec; 22(24):6899-907. PubMed ID: 25456079
[TBL] [Abstract][Full Text] [Related]
18. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
19. Strategies for the design of selective protein kinase inhibitors.
Sawa M
Mini Rev Med Chem; 2008 Oct; 8(12):1291-7. PubMed ID: 18855742
[TBL] [Abstract][Full Text] [Related]
20. N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists.
Carson JR; Coats SJ; Codd EE; Dax SL; Lee J; Martinez RP; Neilson LA; Pitis PM; Zhang SP
Bioorg Med Chem Lett; 2004 May; 14(9):2109-12. PubMed ID: 15080989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
